In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand

Clinical Endocrinology

Volumn 45, Issue 6, 1996, Pages 755-767

  De Herder, W W ^a   Reijs, A E M ^a   Kwekkeboom, D J ^a   Hofland, L J ^a   Nobels, F R E ^a   Oei, H Y ^a   Krenning, E P ^a   Lamberts, S W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; IODINE 123; QUINAGOLIDE; RADIOLIGAND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOPHYSIS TUMOR; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROLACTINOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030469197     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1996.8650876.x     Document Type: Article

References (29)

1. Assies, J., Verhoeff, N.P., Bosch, D.A. & Hofland, L.J. (1993) Intracranial dissemination of a macroprolactinoma. Clinical Endocrinology, 38, 539-546.
2. Bergstrom, M., Muhr, C., Lundberg, P.O. & Langstrom, B. (1991) PET as a tool in lhe clinical evaluation of pituitary adenomas. Journal of Nuclear Medicine, 32, 610-615.
3. Bression, D., Brandi, A.M., Nousbaum, A., Le Dafniet, M., Racadot, J. & Peillon, F. (1982) Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. Journal of Clinical Endocrinology and Metabolism, 55, 589-593.
4. Brue, T., Pellegrini, I., Gunz, G., Morange, I., Dewailly, D., Brownell, J., Enjalbert, A. & Jaquet, P. (1992) Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. Journal of Clinical Endocrinology and Metabolism, 74, 577-584.
5. Cronin, M.J., Cheung, C.Y., Wilson, C.B., Jaffe, R.B. & Weiner, R.I. (1980) [3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. Journal of Clinical Endocrinology and Metabolism, 50, 387-391.
6. Di Chiro, G. & Nelson, K.B. (1962) The volume of the sella turcica. American Journal of Roentgenology, 87, 989-1008.
7. Esiri, M.M., Bevan, J.S., Burke, C.W. & Adams, C.B. (1986) Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. Journal of Clinical Endocrinology and Metabolism, 63, 383-388.
8. Holland, L.J., van Koetsveld, P.M., Verleun, T.M. & Lamberts, S.W. (1989) Glycoprolein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release. Clinical Endocrinology, 30, 601-611.
9. Jaffe, C.A. & Barkan, A.L. (1992) Treatment of acromegaly with dopamine agonists. Endocrinology and Metabolism Clinics of North America, 21, 713-735.
10. Karlsson, F.A., Burman, P., Kampe, O., Westlin, J.E. & Wide, L. (1993) Large somatostatin-insensitive thyrotrophin-secreting pituitary tumour responsive to D-thyroxine and dopamine agonists. Acta Endocrinologica Copenhagen, 129, 291-295.
11. Koga, M., Nakao, H., Arao, M., Sato, B., Noma, K., Morimoto, Y., Kishimoto, S., Mori, S. & Uozumi, T. (1987) Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinologica Copenhagen, 114, 595-602.
12. Kwekkeboom, D.J., de Jong, F.H. & Lamberts, S.W. (1989) Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. Journal of Clinical Endocrinology and Metabolism, 68, 1128-1135.
13. Kwekkeboom, D.J. & Lamberts, S.W. ( 1992) Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma. Clinical Endocrinology, 36, 171-176.
14. Molitch, M.E. (1992) Pathologic hyperprolactinemia. Endocrinology and Metabolism Clinics of North America, 21, 877-901.
15. Muhr, C., Bergstrom, M., Lundberg, P.O., Bergstrom, K., Hartvig, P., Lundqvist, H., Antoni, G. & Langstrom, B. (1986a) Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone. Journal of Computer Assisted Tomography, 10, 175-180.
16. Muhr, C., Bergstrom, M., Lundberg, P.O., Bergstrom, K. & Langstrom, B. (1986b) In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography. Acta Radiologica Supplementum Stockholm, 369, 406-408.
17. Muhr, C., Bergstrom, M., Lundberg, P.O., Bergstrom, K. & Langstrom, B. (1988) Positron emission tomography for the in vivo characterization and follow-up of treatment in pituitary adenomas. In Advances in Pituitary Adenoma Research (eds A. M. Landolt, P. U. Heit, J. Zapf, J. Girard & E. Del Pozo), pp. 163-170. Pergamon Press, Oxford.
18. Muhr, C., Lundberg, P.O., Antoni, G., Bergstrom, K., Hartvig, P., Lundqvist, H., Langstrom, B. & Stalnacke, C.-G. (1984) The uptake of 11C-labelled bromocriptine and methionine in pituitary tumors studied by positron emission tomography. In Trends in the diagnosis and treatment of pituitary adenomas (eds S. W. J. Lamberts, F. J. H. Tilders, E. A. van der Veen & J. Assies), pp. 151-155. Free University Press, Amsterdam.
19. Nomikos, P., Honegger, J., Becker, W., Platsch, G., Feistel, H. Schott, W., Buchfelder, M. & Schrell, U.M.H. (1995) Receptor scrintigraphy and in vitro study of dopamine receptor activity it prolactinomas non-responsive to therapy with dopamine-agonists Experimental and Clinical Endocrinology, 103 (Suppl. 1), 103 (abstr.).
20. Peillon, F., Le Dafniet, M., Garnier, P., Brandi, A.M., Moyse, E., Birman, P., Blumberg-Tick, J., Grouselle, D. & Joubert-Bression, D. (1989) Receptors and neurohormones in human pituitary adenomas. Hormone Research, 31, 13-18.
21. Pellegrini, I., Rasolonjanahary, R., Gunz, G., Bertrand, P., Delivet, S., Jedynak, C.P., Kordon, C., Peillon, F., Jaquet, P. & Enjalbert, A. (1989) Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism, 69, 500-509.
22. Pirker, W., Brucke, T., Riedl, M., Clodi, M., Luger, A., Asenbaum, S., Podreka, I. & Deecke, L. (1994) Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. Journal of Neural Transmission General Section, 97, 235-244.
23. Pirker, W., Riedl, M., Luger, A., Czech, T., Rossler, K., Adsenbaum, S., Angelberger, P., Deecke, L., Podreka, I. & Brucke, T. (1995) SPECT imaging of dopamine D2 receptors in pituitary adenomas using [1231]-epidepride. European Journal of Nuclear Medicine, 22, 833, abstract 436.
24. Samuels, M.H. (1994) Gonadotroph adenomas. Current Therapy in Endocrinology and Metabolism, 5, 52-56.
25. Scillitani, A., Dicembrino, F., Di Fazio, P., Vettori, P.P., D'Angelo, V., Scarabino, T. & Liuzzi, A. (1995) In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. Journal of Clinical Endocrinology and Metabolism, 80, 2523-2525.
26. Serri, O., Marchisio, A.M., Collu, R., Hardy, J. & Somma, M. (1984) Dopaminergic binding sites in human pituitary adenomas other than prolactinomas. Hormone Research, 19, 97-102.
27. Snyder, P.J. (1993) Clinically nonfunctioning pituitary adenomas. Endocrinology and Metabolism Clinics of North America, 22, 163-175.
28. Snyder, P.J. (1995) Extensive personal experience: gonadotroph adenomas. Journal of Clinical Endocrinology and Metabolism, 80, 1059-1061.
29. Verhoeff, N.P., Bemelman, F.J., Wiersinga, W.M. & van Royen, E.A. (1993) Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/ PRL-producing pituitary macroadenoma. European Journal of Nuclear Medicine, 20, 555-561.